Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health of Mexico
This publication has 22 references indexed in Scilit:
- Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 YearsJournal of Adolescent Health, 2012
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose scheduleHuman Vaccines, 2011
- Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategiesPreventive Medicine, 2011
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 VaccineJNCI: Journal of the National Cancer Institute, 2011
- Immunogenicity and Reactogenicity of Alternative Schedules of HPV Vaccine in VietnamJAMA, 2011
- Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América LatinaSalud Pública de México, 2010
- Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young WomenJNCI: Journal of the National Cancer Institute, 2010
- Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and AdolescentsThe Pediatric Infectious Disease Journal, 2007
- Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult WomenPediatrics, 2006